Wedbush cut shares of Ikena Oncology (NASDAQ:IKNA – Free Report) from an outperform rating to a neutral rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm currently has $2.00 price target on the stock, down from their prior price target of $8.00. Wedbush also issued estimates for Ikena Oncology’s […]

Related Keywords

United States , , Ikena Oncology Company Profile , Ikena Oncology Inc , Management Co , Sg Americas Securities , Ikena Oncology , Free Report , Marketbeat Ratings , Oncology Trading Down , Get Free Report , Capital Partners , Capital Management , Ikena Oncology Daily ,